CELZ vs REGN: Which Stock is Better?
Side-by-side comparison of Creative Medical Technology Holdings Inc and Regeneron Pharmaceuticals Inc in 2026
CELZ
Creative Medical Technology Holdings Inc
$2.47
REGN
Regeneron Pharmaceuticals Inc
$750.57
Key Metrics Comparison
| Metric | CELZ | REGN | Winner |
|---|---|---|---|
| Market Cap | $8.61M | $78.87B | REGN |
| P/E Ratio | N/A | 17.98 | REGN |
| EPS (TTM) | $N/A | $41.48 | REGN |
| Revenue Growth | 0.0% | 0.0% | REGN |
| Gross Margin | 63.4% | 44.6% | CELZ |
Analyze CELZ
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CELZ or REGN a better investment?
Comparing CELZ and REGN: Creative Medical Technology Holdings Inc has a market cap of $8.61M while Regeneron Pharmaceuticals Inc has $78.87B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CELZ and REGN?
CELZ (Creative Medical Technology Holdings Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CELZ or REGN?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CELZ or REGN?
REGN has higher revenue growth at 0.0% vs 0.0% for CELZ.
Which company is more profitable: CELZ or REGN?
Creative Medical Technology Holdings Inc (CELZ) has higher gross margins at 63.4% compared to 44.6% for REGN.
Which is the larger company: CELZ or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $78.87B compared to $8.61M for CELZ.
Should I buy CELZ or REGN in 2026?
Both CELZ and REGN have investment merit. CELZ trades at $2.47 while REGN trades at $750.57. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CELZ and REGN stock?
Key differences: Market Cap ($8.61M vs $78.87B), P/E Ratio (N/A vs 18.0x), Revenue Growth (0.0% vs 0.0%), Gross Margin (63.4% vs 44.6%).